MindMed

#EmployeeSpotlight 🌟 Meet Andrew Phelps, Senior Scientist in our Pharmaceutical Development department. He recently joined our team and has quickly become an integral part of ensuring our key program milestones are met with respect to analytical testing and providing technical guidance. His passion for patient-first solutions and commitment to scientific excellence are hallmarks of the MindMed culture. #InsideMindMed

#EmployeeSpotlight 🌟 Meet Allan Morales, our Senior Clinical Trial Associate. Passionate about innovation in brain health, Allan is driven by the potential impact his work at MindMed could have on the quality of life of people living with brain health disorders. Every day, he works to help bring a novel drug candidate closer to reality. #InsideMindMed

We are pleased to welcome Matt Wiley as our new Chief Commercial Officer! With more than 25 years of experience in sales, marketing, and strategic leadership—spanning multiple neuroscience and psychiatric product launches—Matt brings a wealth of expertise to our team. In his new role, he will be a key member of the executive team, leading MindMed's commercial vision and strategy as we prepare for the potential launch of our first product, MM120 ODT, for #GeneralizedAnxietyDisorder (GAD) and #MajorDepressiveDisorder (MDD). Read the press release for more details: https://lnkd.in/eraSJsQM

Generalized Anxiety Disorder (#GAD) is a common and often underdiagnosed mental health disorder that affects millions of people, leading to significant personal and societal burdens. Characterized by excessive, persistent, and unrealistic worry about everyday situations, GAD can cause feelings of fear, ongoing anxiety, and an overwhelming sense of unease. It impacts approximately 10% of U.S. adults—around 20 million people—contributing to reduced work productivity, impaired daily functioning, and lower labor force participation. Despite its widespread impact, there has been little innovation in GAD treatment over the past several decades, with the last new drug approval occurring in 2007. At MindMed, we’re advancing a novel potential treatment option for GAD, currently being studied in two Phase 3 trials. Learn more about our efforts: https://mindmed.co/ #BrainAwarenessWeek #BrainWeek

Today, we reported our Q4 and full year 2024 financial results and business updates. The company hosted a conference call this morning, available for replay. Learn more here: https://bit.ly/4i2HV00

Our CEO, Robert Barrow will participate in a fireside chat at the Leerink Partners Global Healthcare 2025 Conference on Tuesday, March 11th, at 3:40pm EDT. Find details here: https://bit.ly/43F0TFV

Our CMO, Dan Karlin, discussed with Psychiatric Times our MM120 ODT Phase 3 program in patients with #GAD and what this means for the future of psychiatry. Check out the full interview here: https://bit.ly/4jcBZCH

#EmployeeSpotlight 🌟 Meet Michelle M., our dedicated Clinical Trial Manager at MindMed. Starting her career in academia, Michelle transitioned to biotech driven by her passion for helping people with brain health disorders. Her journey reflects our mission to bring innovative mental health treatments to those in need. #InsideMindMed

#ICYMI We recently announced the dosing of the first patients in our Voyage and Panorama Phase 3 studies evaluating MM120 ODT for #GeneralizedAnxietyDisorder. To the patients participating in this study, thank you for your courage and trust in our clinical study. Your participation is critical to advancing a novel treatment and bringing hope to others with GAD. We also extend our gratitude to the investigators and study coordinators for their continued support. Data from the 12-week double-blind from both studies is expected in 2026. Learn more: https://bit.ly/42QGCfN

 At MindMed, we are committed to transforming the treatment landscape for brain health disorders through evidence-based innovative solutions. Learn more about our programs and research: https://bit.ly/40MooJW